 |
|
|
| |
SOFOSBUVIR/LEDIPASVIR IN RETREATMENT OF HCV GENOTYPE-1 PATIENTS WHO PREVIOUSLY FAILED SOFOSBUVIR/RIBAVIRIN THERAPY
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Anu Osinusi1,2, Miriam Marti1, Anita Kohli3,4, Eric Meissner 1, Kerry Townsend1, Amy Nelson1, Rachel Silk3, Xiaozhen Zhang 1, William T. Symonds5, John McHutchison5, Michael Polis 1, Henry Masur4, Shyam Kottilil 1 for the NIAID/CC Hepatitis C SYNERGY team1,3,4
1Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, 2Dept of Infectious Diseases, University of Maryland, Baltimore, 3CMRP, SAIC-Frederick Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland , 4Critical Care Medicine Department, NIH, Bethesda, Maryland , 5Gilead Sciences, Foster City, California
|
| |
|
|
|
|
|
